Back to mobile site

More on EOLS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+55.6% Growth)
- Ratings (7.7 Score)

Upcoming Events

- Earnings (11/5/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Evolus (NQ:EOLS)
Delayed: 8.98 +0.01 (0.11%)
Prev. Close $8.97  
Open$8.98 
52 Wk High$ 
52 Wk Low$ 
Day High$8.98 
Day Low$8.98 
P/E N/A  
EPS$ 
Volume280 

Friends, Peers and Foes (?): TLX, ALC, APYX, BSX, CARL (more...)

Aug 5, 2026 04:57 PM Form 10-Q Evolus, Inc. For: Jun 30
Aug 5, 2026 04:21 PM Form 8-K Evolus, Inc. For: Aug 05
Aug 5, 2026 04:17 PM Evolus (EOLS) Misses Q2 EPS by 8c; Offers Guidance
Aug 5, 2026 04:05 PM Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Aug 4, 2026 08:46 AM Form 8-K Evolus, Inc. For: Aug 03
Aug 4, 2026 08:30 AM Evolus expands Symatese deal to sell Estyme in Canada and Oceania
Aug 4, 2026 08:30 AM Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
Jul 22, 2026 08:30 AM Evolus to Report Second Quarter Financial Results on August 5, 2026
Jul 10, 2026 04:05 PM Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 8, 2026 09:04 AM Form 8-K Evolus, Inc. For: Jul 07
View All Articles

Entities mentioned with EOLS

View All Entities